Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.
Publication
, Journal Article
Gauthier, S; Alam, J; Fillit, H; Iwatsubo, T; Liu-Seifert, H; Sabbagh, M; Salloway, S; Sampaio, C; Sims, JR; Sperling, B; Sperling, R ...
Published in: J Prev Alzheimers Dis
2019
Combination therapy is expected to play an important role for the treatment of Alzheimer's disease (AD). In October 2018, the European Union-North American Clinical Trials in Alzheimer's Disease Task Force (EU/US CTAD Task Force) met to discuss scientific, regulatory, and logistical challenges to the development of combination therapy for AD and current efforts to address these challenges. Task Force members unanimously agreed that successful treatment of AD will likely require combination therapy approaches that target multiple mechanisms and pathways. They further agreed on the need for global collaboration and sharing of data and resources to accelerate development of such approaches.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Prev Alzheimers Dis
DOI
EISSN
2426-0266
Publication Date
2019
Volume
6
Issue
3
Start / End Page
164 / 168
Location
Switzerland
Related Subject Headings
- Treatment Outcome
- Humans
- Drug Therapy, Combination
- Drug Development
- Clinical Trials as Topic
- Animals
- Alzheimer Disease
- Advisory Committees
- 5204 Cognitive and computational psychology
- 5202 Biological psychology
Citation
APA
Chicago
ICMJE
MLA
NLM
Gauthier, S., Alam, J., Fillit, H., Iwatsubo, T., Liu-Seifert, H., Sabbagh, M., … Aisen, P. (2019). Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force. J Prev Alzheimers Dis, 6(3), 164–168. https://doi.org/10.14283/jpad.2019.12
Gauthier, S., J. Alam, H. Fillit, T. Iwatsubo, H. Liu-Seifert, M. Sabbagh, S. Salloway, et al. “Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.” J Prev Alzheimers Dis 6, no. 3 (2019): 164–68. https://doi.org/10.14283/jpad.2019.12.
Gauthier S, Alam J, Fillit H, Iwatsubo T, Liu-Seifert H, Sabbagh M, et al. Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force. J Prev Alzheimers Dis. 2019;6(3):164–8.
Gauthier, S., et al. “Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.” J Prev Alzheimers Dis, vol. 6, no. 3, 2019, pp. 164–68. Pubmed, doi:10.14283/jpad.2019.12.
Gauthier S, Alam J, Fillit H, Iwatsubo T, Liu-Seifert H, Sabbagh M, Salloway S, Sampaio C, Sims JR, Sperling B, Sperling R, Welsh-Bohmer KA, Touchon J, Vellas B, Aisen P. Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force. J Prev Alzheimers Dis. 2019;6(3):164–168.
Published In
J Prev Alzheimers Dis
DOI
EISSN
2426-0266
Publication Date
2019
Volume
6
Issue
3
Start / End Page
164 / 168
Location
Switzerland
Related Subject Headings
- Treatment Outcome
- Humans
- Drug Therapy, Combination
- Drug Development
- Clinical Trials as Topic
- Animals
- Alzheimer Disease
- Advisory Committees
- 5204 Cognitive and computational psychology
- 5202 Biological psychology